Tarsier Pharma

Company profile

Tarsier Pharma company profile

Tarsier Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases and is currently being developed as both eye drops and intravitreal injections. Ocular inflammations are a group of diseases affecting the front and back of the eye. Non-infectious anterior and posterior uveitis is the most known ocular inflammatory disease. However, ocular inflammation is a critical underlying mechanism in the pathology of other inflammatory eye diseases, such as non-evaporative dry eye, diabetic macular edema (DME), and dry age-related macular degeneration (AMD). Hundreds of millions of people in all age groups are suffering from ocular inflammatory diseases worldwide, conditions that pose severe risks of vision loss and blindness.